I tend to agree, I doubt the fda is looking to expand the
I tend to agree, I doubt the fda is looking to expand the indication on their own. The problem is that they depend on some level of safety issues and/or non-efficacy. Nothing is 100% and leronlimab is darn near close to that. The fda has to be feeling like something cant be this good and that is why they want as much safety data as possible. They want to make sure they don’t approve a drug this good and find out later there is a problem they missed. Not that there is a problem,btw. The fda is not going to extrapolate data and decide this is approved as a mono treatment without a pivotal mono trail with clean data.
On the other hand, the fda is under pressure to speed up the process and not hold back on revolutionary drugs that can save lives. This might be a win -win -win for the fda, cytodyn and the patients. But, Nader sure is not inferring that discussion is happening and Nader historically can’t hold onto that kind of potential without telling the world. Maybe because it involves the fda and he is being extra careful but I think the fda sees the combo approval as good enough as is for the first of many approvals.
It will be more interesting to see what happens for off-label use after the combo approval, that will show the acceptance by doctors more than anything.
2
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Transforming Waste Management through AI The waste and recycling game just got a facelift with Routeware's latest AI-powered tools. Right out of Austin, Texas, they're throwing down with Routeware Pulse, a fresh AI data and analytics platform that promises to revolutionize how operators handle their reporting and decision-making. It’s no fluff—they’re talking...
Continue Reading
A Bold New Chapter for Ford Foundation Forget your typical, rigid funding structures; the Ford Foundation is shaking things up. This ain't about just doling out cash and controlling the reigns anymore. Nope, they've pulled the curtain aside to reveal plans for a more agile, empowering approach to sustaining nonprofit partners globally. On the table is a guaranteed 50%...
Continue Reading
Eyewear ain’t just about seeing clearly anymore—it’s fashion with a capital ‘F’. The CHARMANT Japanese Made brand decided to foist this idea upon the world, putting their money where your eyeballs are, by injecting a dose of trendy glam into what they already do so well: comfort. Fusion of Style and Comfort Catch this: CHARMANT hit the global stage back in June...
Continue Reading
Facing Down Delays with Trimble's New AI Tool In an industry where timelines are often more of a suggestion than a rule, Trimble's dropping a new hammer with its Connect Scheduling solution. This isn't your garden-variety update; it's a full-fledged assault on the inefficiencies plaguing construction scheduling today. With Trimble Connect Scheduling, folks on the ground...
Continue Reading
Revolution in Sleep Health The paper has officially announced a promising shift in sleep apnea treatment. Eli Lilly's Foundayo, revealed through a Phase 3 clinical program, is looking to tackle obstructive sleep apnea (OSA) with unprecedented potential. Forget the traditional methods—this small molecule GLP-1 receptor agonist could be a game changer for folks plagued by...
Continue Reading
A New Lens on Korea Here's a fresh angle for the globetrotters: Wego, the travel app juggernaut, is shaking hands with the Korea Tourism Organization (KTO) to shift how folks from the Middle East and North Africa view Korea. Forget the typical Seoul itinerary loaded with K-Pop and BBQ haunts—this collaboration's geared to spotlight Korea’s lesser-known gems. Travel...
Continue Reading
Navigating the Maze of Nursing Home Choices Every family dreads the moment when choosing a nursing home becomes necessary. It's like trying to make sense of a puzzle with too many moving pieces. Fortunately, the latest rankings from U.S. News & World Report might just be the lifesaver families need right now as they navigate this often fraught decision. A Look into the...
Continue Reading
Rivada's Outernet: A New Era of Connectivity Forget the terrestrial wires; we're talking about 600 satellites playing a space-age game of telephone. That's Rivada's Outernet for you, an orbital mesh network that's about to upend the very nature of global communications. Telespazio's new partnership with Rivada is like strapping a rocket onto secure connectivity in the...
Continue Reading
Ringside Seat to Western Digital's Legal Turbulence If there's one thing that'll make an investor's hair stand on end, it's the whisper of fiduciary breaches. Western Digital Corporation (NASDAQ:WDC) just took a hit from Levi & Korsinsky, LLP, who've launched a full-scale investigation into potential breaches of fiduciary duties by select officers and directors. When a...
Continue Reading
Riding the Small Business Tsunami in Idaho You don't hear it every day, but Idaho's small business scene is hotter than a frypan—a nod to the entrepreneurial fire blazing in the state, and Zions Bank is holding the torch. In 2026, despite dealing with the uphill battles of inflation, tariffs, and labor scarcity, those entrepreneurs still managed to carve out a spot at...
Continue Reading
